Vienna, Austria

Chris Oostenbrink

This inventor holds 1 USPTO granted patent. Top assignee: Acib Gmbh. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chris Oostenbrink. Retrieved from https://idiyas.com/inventor/chris-oostenbrink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chris Oostenbrink: Innovator in Biochemistry

Introduction

Chris Oostenbrink is a notable inventor based in Vienna, Austria. He has made significant contributions to the field of biochemistry, particularly through his innovative work on caspase-2 variants. His research has implications for understanding apoptosis and cellular processes.

Latest Patents

Chris holds 1 patent related to his work on caspase-2 variants. This patent reflects his commitment to advancing scientific knowledge and developing new solutions in biochemistry.

Career Highlights

Chris is currently employed at Acib GmbH, where he continues to push the boundaries of research and innovation. His role at the company allows him to collaborate with other experts in the field and contribute to groundbreaking projects.

Collaborations

Some of Chris's coworkers include Monika Cserjan-Puschmann and Christina Kroess. Their collaborative efforts enhance the research environment at Acib GmbH and foster innovation.

Conclusion

Chris Oostenbrink is a dedicated inventor whose work in biochemistry is paving the way for future advancements. His contributions, particularly in the area of caspase-2 variants, highlight the importance of innovation in scientific research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…